CStone Pharmaceuticals Full Year 2024 Earnings: Misses Expectations

CStone Pharmaceuticals (HKG:2616) Full Year 2024 Results

Key Financial Results

• Revenue: CN¥407.2m (down 12% from FY 2023).
• Net loss: CN¥91.2m (loss narrowed by 75% from FY 2023).
• CN¥0.071 loss per share (improved from CN¥0.29 loss in FY 2023).

This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality.

2616 Post-Clinical Trial Products

• Approved (during full year): 5.

All figures shown in the chart above are for the trailing 12 month (TTM) period

CStone Pharmaceuticals Revenues and Earnings Miss Expectations

Revenue missed analyst estimates by 15%. Earnings per share (EPS) also missed analyst estimates.

Looking ahead, revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 25% growth forecast for the Biotechs industry in Hong Kong.

Performance of the Hong Kong Biotechs industry.

The company's shares are up 1.8% from a week ago.

Risk Analysis

You should always think about risks. Case in point, we've spotted 1 warning sign for CStone Pharmaceuticals you should be aware of.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.